Background
GHK-Cu has been commercially applied in cosmetic preparations for decades, but controlled experimental data on its wound healing activity had been sparse relative to its widespread use. This preclinical study used a standardized full-thickness excision wound model in rats to quantitatively assess GHK-Cu’s effects on wound closure rate, histological tissue quality, and inflammatory markers.
Methods
Sprague-Dawley rats received standardized 1.5 cm² full-thickness excisional wounds on the dorsum. Treatment groups:
- GHK-Cu (5 µM in hydrogel) applied topically twice daily
- Vehicle control (hydrogel without GHK-Cu)
- Positive control (silver sulfadiazine)
Outcomes measured:
- Wound area (planimetry) at days 3, 7, 14
- Histology: collagen density (Masson’s trichrome), inflammatory cells (H&E)
- Gene expression: TGF-β1, IL-1β, VEGF via RT-PCR at wound margins
Key Findings
Wound Closure:
- Day 7: GHK-Cu wounds 30% smaller than vehicle (p < 0.01)
- Day 14: GHK-Cu wounds achieved 95% closure vs. 78% in vehicle control
Histological Findings:
- Significantly greater collagen fiber density and organization in GHK-Cu treated wounds
- Reduced polymorphonuclear (inflammatory) cell infiltration at day 7
- Earlier angiogenesis: greater VEGF expression and microvessel density at wound margins
Gene Expression (Day 7 wound margin):
| Gene | GHK-Cu vs. Vehicle |
|---|---|
| TGF-β1 (pro-healing) | ↑ 2.1× |
| VEGF | ↑ 1.8× |
| IL-1β (inflammatory) | ↓ 0.6× |
| Collagen I | ↑ 1.9× |
Clinical Significance
These data provide mechanistic grounding for GHK-Cu’s wound healing properties at multiple levels — inflammation resolution, angiogenesis, and collagen matrix assembly. The 30% acceleration in wound closure at day 7 is a meaningful effect size in wound healing research.
For aesthetic medicine and dermatology applications:
- Post-procedure recovery: Topical GHK-Cu after laser resurfacing, microneedling, or surgery could accelerate healing and improve scar quality
- Collagen remodeling: The collagen upregulation profile supports its use in photodamage reversal and anti-aging protocols
- Anti-inflammatory window: Early post-wound anti-inflammatory activity may reduce hypertrophic scar formation risk
Limitations
- Rat excisional wound model; human wound healing dynamics differ (more complex immune environment, different skin architecture)
- Topical application — systemic or SC GHK-Cu pharmacology is separate from these findings
- No human clinical validation of wound healing endpoints
- Concentration used (5 µM topical) needs translation to effective clinical formulations